{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66"},{"groupId":"OG001","value":"73"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"70"}],"units":"Participants"}],"description":"ACR20 responders are participants with at least 20% improvement from baseline for TJC, SJC, and at least 3 of the 5 remaining core set measures: HAQ-DI which measured participants perceived degree of difficulty performing daily activities, CRP and ESR, PAAP-VAS, PtGADA-VAS, or PhGA-VAS. Missing values were imputed using NRI, where non-responders were participants who discontinued the study prior to the completion of Part B. Percentage of participants achieving ACR20 response = (number of ACR20 responders) / (number of participants treated) \\* 100.","groups":[{"description":"Participants on background methotrexate therapy who were administered 1 mg, 2 mg, 4 mg baricitinib (LY3009104) capsule or placebo capsule, orally once daily for 12 weeks in Part A received 4 mg baricitinib (LY3009104) and 1 placebo tablet orally once daily for 52 weeks in Part B.","id":"OG000","title":"Combined 4 mg Baricitinib (LY3009104) (Part B)"},{"description":"Participants on background methotrexate therapy who were administered 1 mg, 2 mg, 8 mg baricitinib (LY3009104) capsule or placebo capsule, orally once daily for 12 weeks in Part A received 2 x 4 mg baricitinib (LY3009104) tablets orally once daily for 52 weeks in Part B.","id":"OG001","title":"Combined 8 mg Baricitinib (LY3009104) (Part B)"}],"paramType":"NUMBER","populationDescription":"All participants who received any amount of study drug in Part B.","reportingStatus":"POSTED","timeFrame":"Baseline up to 64 weeks","title":"Percentage of Participants Who Achieved an ACR20 Response at 64 Weeks","type":"SECONDARY","unitOfMeasure":"percentage of participants"}